Category: Peptide Science
-
What is the mechanistic relationship between BPC-157’s claimed angiogenic effects and VEGFR2 signaling, and could that same mechanism plausibly accelerate occult tumor growth in users with undiagnosed neoplasia?
No direct evidence ties BPC-157 to VEGFR2 activation, but the peptide’s undocumented status in a field where every VEGF-boosting peptide accelerates occ
-
In psoriasis, why do thymic peptides (thymosin α1, thymulin) appear to help some patients despite the disease being driven by Th17 hyperactivity — is it Treg restoration or something subtler about T-cell repertoire?
Thymic peptides improve psoriasis not by blunting Th17 force outright, but by re-instituting thymic quality-control that deletes the highest-affinity sk
-
What is the actual molecular basis of “peptide tachyphylaxis” — receptor downregulation, antibody formation, post-receptor desensitization — and which mechanism dominates for each major class?
For GPCR-targeting peptides receptor down-regulation dominates tachyphylaxis; for ion-channel blockers it is post-receptor desensitisation; for chemical
-
How does GHK-Cu interact with the wound-healing senescence-associated secretory phenotype (SASP), and could topical GHK-Cu actually accelerate senescence in some skin cell populations via copper-mediated oxidative stress?
GHK-Cu is a double-edged copper shuttle – in low nanomolar doses it suppresses the SASP by resetting antioxidant and inflammatory genes, but once copper
-
What would a supply chain economist notice about the global gray-market peptide industry that practitioners don’t — particularly around the China → EU/Romania logistics pipeline and how it constrains real-world product quality?
The China→EU gray-market peptide route is a cold-chain desert where every logistics cost saved is paid for by exponential, chemistry-driven potency loss
-
If applied epidemiology methods (target trial emulation) were used on the existing peptide self-experimenter forums, what causal estimates could actually be extracted from the noise?
Target-trial emulation on peptide self-experimenter forums can yield defensible causal estimates only when the analysis is shrunk to chronologically-tim
-
What does evolutionary biology say about why short bioactive peptides (5–15 residues) are so over-represented in signaling, and what does that imply for the design space available to novel therapeutic peptides?
Evolution keeps signaling peptides short because their fold-free, low-cost architecture turns random mutations into instant, high-impact functions—an ev
-
Could the entire “peptides are safer than steroids” framing be a category error, given that we have decades of human safety data on AAS and essentially none on most performance peptides?
The claim that peptides are safer than steroids is a category error because it pits a well-characterized, decades-old risk curve (AAS) against an almost
-
Is Semax’s nootropic reputation in the West a translation artifact — Russian clinical practice uses it almost exclusively for stroke recovery, not cognitive enhancement in healthy adults?
Semax’s Western nootropic halo is a selective reinterpretation; in its homeland it remains a short-course stroke-recovery drug with no published evidenc
-
If alopecia areata is principally a JAK-STAT-driven autoimmune disease, what is the actual mechanistic basis for any peptide (GHK-Cu, copper tripeptide, thymulin) producing regrowth — or are users just observing telogen effluvium recovery from unrelated stress reduction?
The literature offers no evidence that GHK-Cu or related peptides intercept the JAK-STAT auto-immunity of alopecia areata; observed regrowth is almost c